SDF-1/CXCR4/CXCR7 is pivotal for vascular smooth muscle cell proliferation and chronic allograft vasculopathy
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
SDF-1/CXCR4/CXCR7 is pivotal for vascular smooth muscle cell proliferation and chronic allograft vasculopathy
Authors
Keywords
-
Journal
TRANSPLANT INTERNATIONAL
Volume 28, Issue 12, Pages 1426-1435
Publisher
Wiley
Online
2015-08-12
DOI
10.1111/tri.12651
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Interacting Mechanisms in the Pathogenesis of Cardiac Allograft Vasculopathy
- (2014) Jordan S. Pober et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Inhibition of Innate Co-Receptor TREM-1 Signaling Reduces CD4+T Cell Activation and Prolongs Cardiac Allograft Survival
- (2013) G. Schiechl et al. AMERICAN JOURNAL OF TRANSPLANTATION
- The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization
- (2013) J. Hoellenriegel et al. BLOOD
- Hematopoietic Stem and Progenitor Cell Mobilization in Mice and Humans by a First-in-Class Mirror-Image Oligonucleotide Inhibitor of CXCL12
- (2013) A Vater et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Mechanisms of human smooth muscle cell proliferation and transplant vasculopathy induced by HLA class I antibodies: In vitro and in vivo studies
- (2012) Magali Trayssac et al. HUMAN IMMUNOLOGY
- Dual Blockade of the Homeostatic Chemokine CXCL12 and the Proinflammatory Chemokine CCL2 Has Additive Protective Effects on Diabetic Kidney Disease
- (2011) Murthy N. Darisipudi et al. AMERICAN JOURNAL OF PATHOLOGY
- SDF-1α Induction in Mature Smooth Muscle Cells by Inactivation of PTEN Is a Critical Mediator of Exacerbated Injury-Induced Neointima Formation
- (2011) Raphael A. Nemenoff et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- The Registry of the International Society for Heart and Lung Transplantation: Twenty-eighth Adult Lung and Heart-Lung Transplant Report—2011
- (2011) Jason D. Christie et al. JOURNAL OF HEART AND LUNG TRANSPLANTATION
- Interleukin-33 prolongs allograft survival during chronic cardiac rejection
- (2011) Stefan M. Brunner et al. TRANSPLANT INTERNATIONAL
- Long-Term Renal Allograft Survival in the United States: A Critical Reappraisal
- (2010) K. E. Lamb et al. AMERICAN JOURNAL OF TRANSPLANTATION
- CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression
- (2010) Xueqing Sun et al. CANCER AND METASTASIS REVIEWS
- TGF-β, IL-6, IL-17 and CTGF direct multiple pathologies of chronic cardiac allograft rejection
- (2010) Adam J Booth et al. Immunotherapy
- Risk factors associated with cytomegalovirus infection in heart transplant patients: a prospective, epidemiological study
- (2010) J.F. Delgado et al. Transplant Infectious Disease
- Critical Role for IL-6 in Hypertrophy and Fibrosis in Chronic Cardiac Allograft Rejection
- (2009) J. A. Diaz et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Podocytes produce homeostatic chemokine stromal cell-derived factor-1/CXCL12, which contributes to glomerulosclerosis, podocyte loss and albuminuria in a mouse model of type 2 diabetes
- (2009) S. G. Sayyed et al. DIABETOLOGIA
- Human Leukocyte Antigen Antibodies and Chronic Rejection: From Association to Causation
- (2009) Paul I. Terasaki et al. TRANSPLANTATION
- Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction
- (2008) S. M. Devine et al. BLOOD
- Essential but differential role for CXCR4 and CXCR7 in the therapeutic homingof human renal progenitor cells
- (2008) Benedetta Mazzinghi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Immunologic targets in the etiology of allograft vasculopathy: Endothelium versus media
- (2008) Maria Currie et al. TRANSPLANT IMMUNOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started